

VIA EFS Web  
Date of Filing: November 23, 2009

Attorney Docket No. CST- 209  
PAIR Customer No.: 31012

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Polakiewicz *et al.*  
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.  
SERIAL NUMBER: 10/694,874 EXAMINER: Ewoldt, Gerald R  
FILING DATE: November 13, 2003 ART UNIT: 1644  
FOR: ANTIBODIES SPECIFIC FOR PHOSPHORYLATED INSULIN RECEPTOR SUBSTRATE-1/2  
(SER1101/SER1149) AND USES THEREOF

Mail Stop: Amendment  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313

### AMENDMENT AND RESPONSE (37 C.F.R. §§1.111, 1.121)

This paper is filed in response to the Office Action dated October 13, 2009 (hereinafter the "Action") that has issued in connection with the above-identified patent application (hereinafter "Application"). Applicant previously submitted a response to the Action on November 19, 2009 that may not have been fully compliant with the requirements of 37 C.F.R. §1.121. Accordingly, Applicant is re-responding to the Action herein. A response to the Action is due on or before December 13, 2009.

The Action states that the specification of the Application is not compliant with 37 C.F.R. § 1.821 through 1.825 because the amino acid sequences set forth in Figure 8 are not identified by a SEQ ID NO. Accordingly, Applicant submits herewith an amendment to the specification and the drawings that properly identifies the sequences in Figure 8 by SEQ ID NO's.

*Amendments to the Specification:* page 2 of this paper

*Amendments to the Drawings:* page 3 of this paper

*Remarks:* page 4 of this paper.

This Amendment complies with the requirements of 37 C.F.R. §1.121.